These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 20189387

  • 1. Identification of amide bioisosteres of triazole oxytocin antagonists.
    Brown A, Ellis D, Wallace O, Ralph M.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2224-8. PubMed ID: 20189387
    [Abstract] [Full Text] [Related]

  • 2. Identification of a urea bioisostere of a triazole oxytocin antagonist.
    Brown A, Ellis D, Wallace O, Ralph M.
    Bioorg Med Chem Lett; 2010 Mar 15; 20(6):1851-3. PubMed ID: 20172721
    [Abstract] [Full Text] [Related]

  • 3. Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.
    Brown A, Brown TB, Calabrese A, Ellis D, Puhalo N, Ralph M, Watson L.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):516-20. PubMed ID: 19963374
    [Abstract] [Full Text] [Related]

  • 4. Aryloxypyrazines as highly selective antagonists of Oxytocin.
    Brown A, Ellis D, Pearce D, Ralph M, Sciammetta N.
    Bioorg Med Chem Lett; 2009 May 15; 19(10):2634-6. PubMed ID: 19376698
    [Abstract] [Full Text] [Related]

  • 5. Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.
    Brown A, Brown L, Brown TB, Calabrese A, Ellis D, Puhalo N, Smith CR, Wallace O, Watson L.
    Bioorg Med Chem Lett; 2008 Oct 01; 18(19):5242-4. PubMed ID: 18778939
    [Abstract] [Full Text] [Related]

  • 6. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.
    J Pept Sci; 2005 Oct 01; 11(10):593-608. PubMed ID: 15880385
    [Abstract] [Full Text] [Related]

  • 7. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8.
    Flouret G, Chaloin O, Slaninová J.
    J Pept Sci; 2003 Jun 01; 9(6):393-401. PubMed ID: 12846485
    [Abstract] [Full Text] [Related]

  • 8. Synthesis, 3D-QSAR, and docking studies of 1-phenyl-1H-1,2,3-triazoles as selective antagonists for beta3 over alpha1beta2gamma2 GABA receptors.
    Alam MS, Huang J, Ozoe F, Matsumura F, Ozoe Y.
    Bioorg Med Chem; 2007 Aug 01; 15(15):5090-104. PubMed ID: 17544280
    [Abstract] [Full Text] [Related]

  • 9. The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
    Napier S, Wishart G, Arbuckle W, Baker J, Barn D, Bingham M, Brown A, Byford A, Claxton C, Craighead M, Buchanan K, Fielding L, Gibson L, Goodwin R, Goutcher S, Irving N, MacSweeney C, Milne R, Mort C, Presland J, Sloan H, Thomson F, Turnbull Z, Young T.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):3163-7. PubMed ID: 21458261
    [Abstract] [Full Text] [Related]

  • 10. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY, Wo NC, Cheng LL, Manning M.
    J Pharmacol Exp Ther; 1996 May 15; 277(2):999-1003. PubMed ID: 8627583
    [Abstract] [Full Text] [Related]

  • 11. Non-peptide oxytocin agonists.
    Pitt GR, Batt AR, Haigh RM, Penson AM, Robson PA, Rooker DP, Tartar AL, Trim JE, Yea CM, Roe MB.
    Bioorg Med Chem Lett; 2004 Sep 06; 14(17):4585-9. PubMed ID: 15357997
    [Abstract] [Full Text] [Related]

  • 12. Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.
    Abdi MH, Beswick PJ, Billinton A, Chambers LJ, Charlton A, Collins SD, Collis KL, Dean DK, Fonfria E, Gleave RJ, Lejeune CL, Livermore DG, Medhurst SJ, Michel AD, Moses AP, Page L, Patel S, Roman SA, Senger S, Slingsby B, Steadman JG, Stevens AJ, Walter DS.
    Bioorg Med Chem Lett; 2010 Sep 01; 20(17):5080-4. PubMed ID: 20673717
    [Abstract] [Full Text] [Related]

  • 13. The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.
    Borthwick AD, Liddle J.
    Med Res Rev; 2011 Jul 01; 31(4):576-604. PubMed ID: 20027670
    [Abstract] [Full Text] [Related]

  • 14. Design and optimization of potent, selective antagonists of Oxytocin.
    Brown A, Brown L, Ellis D, Puhalo N, Smith CR, Wallace O, Watson L.
    Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4278-81. PubMed ID: 18639455
    [Abstract] [Full Text] [Related]

  • 15. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, Allen MJ, Perren M, Shabbir SS, Woollard PM, Wyatt PG.
    J Med Chem; 2005 Nov 03; 48(22):6956-69. PubMed ID: 16250654
    [Abstract] [Full Text] [Related]

  • 16. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
    Scott JD, Miller MW, Li SW, Lin SI, Vaccaro HA, Hong L, Mullins DE, Guzzi M, Weinstein J, Hodgson RA, Varty GB, Stamford AW, Chan TY, McKittrick BA, Greenlee WJ, Priestley T, Parker EM.
    Bioorg Med Chem Lett; 2009 Nov 01; 19(21):6018-22. PubMed ID: 19800231
    [Abstract] [Full Text] [Related]

  • 17. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 2001 Sep 01; 7(9):449-65. PubMed ID: 11587184
    [Abstract] [Full Text] [Related]

  • 18. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Sep 01; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 19. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.
    Arban R, Bianchi F, Buson A, Cremonesi S, Di Fabio R, Gentile G, Micheli F, Pasquarello A, Pozzan A, Tarsi L, Terreni S, Tonelli F.
    Bioorg Med Chem Lett; 2010 Sep 01; 20(17):5044-9. PubMed ID: 20674355
    [Abstract] [Full Text] [Related]

  • 20. Structural Consequences of the 1,2,3-Triazole as an Amide Bioisostere in Analogues of the Cystic Fibrosis Drugs VX-809 and VX-770.
    Doiron JE, Le CA, Bacsa J, Breton GW, Martin KL, Aller SG, Turlington M.
    ChemMedChem; 2020 Sep 16; 15(18):1720-1730. PubMed ID: 32385907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.